


1614
Tew

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19721

In Re Application Of: David Morritz De Kretser, et al.



Application No.	Filing Date	Examining Office	Customer No.	Group Art Unit	Confirmation No.
10/575,049	April 5, 2006	Unassigned	23389	Unassigned	Unassigned

Title:

THERAPEUTIC METHOD

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.

19721

In Re Application of: David Morritz De Kretser, et al.



Application No.

10/575,049

Filing Date

April 5, 2006

Examiner

Unassigned

Customer No.

23389

Group Art Unit

Unassigned

Confirmation No.

Unassigned

Title:

THERAPEUTIC METHOD

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa	
(Date)	
Signature	
Typed or Printed Name of Person Signing Certificate	

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on	
October 24, 2006	
(Date)	
Signature of Person Mailing Correspondence	
Xiaochun Zhu	
Typed or Printed Name of Person Mailing Certificate	

*This certificate may only be used if paying by deposit account.

Signature

Dated: October 24, 2006

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David Morritz De Kretser, et al.

Examiner: Unassigned

Serial No.: 10/575,049

Art Unit: Unassigned

Filed: April 5, 2006

Docket: 19721

For: THERAPEUTIC METHOD

Dated: October 24, 2006

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. de Winter J.P. et al., "Follistatins Neutralize Activin Bioactivity by Inhibition of Activin Binding to its Type II Receptors", *Molecular and Cellular Endocrinology* 116(1):105-114 (1996);
2. Yu E.W. et al., "Suppression of IL-6 Biological Activities by Activin A and Implications for Inflammatory Arthropathesis", *Clinical and Experimental Immunology* 112:126-132 (1998);
3. Jones K.L. et al., "Activin A Release into the Circulations is an Early Event in Systemic Inflammation and Precedes the Release of Follistatin", *Endocrinology* 141(5):1905-1908 (2000);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 24, 2006


Xiaochun Zhu

4. Phillips D.J. et al., "Evidence for Activin A and Follistatin Involvement in the Systemic Inflammatory Response", *Molecular and Cellular Endocrinology* 180(1-2):155-162 (2001); and
5. Gribi R. et al., "Expression of Activin A in Inflammatory Arthropathies", *Molecular and Cellular Endocrinology* 180(1-2):163-167 (2001).

The references were cited in an International Search Report dated December 22, 2004 received from the Australian Patent Office. Applicants are submitting a copy of the above-cited references. Applicants previously submitted a copy of the International Search Report on April 5, 2006. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

XZ:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 7-80) PATENT AND TRADEMARK OFFICE

LIST OF PRIOR ART CITED BY APPLICANT


(Use several sheets if necessary)

Atty. Docket No. (Optional)

19721

Application Number

10/575,049



Applicant(s)

David Morritz De Kretser, et al.

Filing Date

April 5, 2006

Group Art Unit

Unassigned

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		de Winter J.P. et al., "Follistatins Neutralize Activin Bioactivity by Inhibition of Activin Binding to its Type II Receptors", <i>Molecular and Cellular Endocrinology</i> 116(1):105-114 (1996)
		Yu E.W. et al., "Suppression of IL-6 Biological Activities by Activin A and Implications for Inflammatory Arthropathesis", <i>Clinical and Experimental Immunology</i> 112:126-132 (1998)
		Jones K.L. et al., "Activin A Release into the Circulations is an Early Event in Systemic Inflammation and Precedes the Release of Follistatin", <i>Endocrinology</i> 141(5):1905-1908 (2000)
		Phillips D.J. et al., "Evidence for Activin A and Follistatin Involvement in the Systemic Inflammatory Response", <i>Molecular and Cellular Endocrinology</i> 180(1-2):155-162 (2001)
		Gribi R. et al., "Expression of Activin A in Inflammatory Arthropathies", <i>Molecular and Cellular Endocrinology</i> 180(1-2):163-167 (2001)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.